REFERENCES
1. Digumarti R, Koyyala VP. Patterns of Care of Childhood Cancers in
India [Internet]. Central Nervous System Tumors. IntechOpen; 2021
[cited 2022 Feb 1]. Available from:
https://www.intechopen.com/chapters/75757 DOI: 10.5772/intechopen.96709
2. Radhakrishnan V, Howard S, Lam C. Pediatric cancers in India: The
forgotten disease. Cancer Research, Statistics, and Treatment. 2021 Jan
1;4(1):6. DOI: 10.4103/crst.crst_375_20
3 Radhakrishnan V. Drug pricing: A major barrier to access to cancer
care in India. Cancer Research, Statistics, and Treatment. 2021 Apr
1;4(2):195. DOI: 10.4103/crst.crst_66_21
4 D’Souza V, Palatty P, George T, Adnan M, Rao S, Baliga M. Financial
audit of wastage of anticancer drugs: Pilot study from a tertiary care
center in India. Indian J Cancer. 2019;56(2):146. DOI:
10.4103/ijc.IJC_169_18
5 Erenay FS, Horton S. “Financial audit of wastage of anticancer drugs:
Pilot study from a tertiary care center of India”: A commentary. Indian
Journal of Cancer. 2019 Apr 1;56(2):99-100.
DOI: 10.4103/ijc.IJC_125_19
6. Gopisankar M, Wahlang J, Jagtap V, Sarkar C, Purnima Devi L, Harris
C. Cancer chemotherapy drug wastage in a tertiary care hospital in
India—A 3‐month prospective and 1‐year retrospective study. Br J Clin
Pharmacol. 2019 Oct;85(10):2428–35. DOI:
https://doi.org/10.1111/bcp.14064
7. Truong J, Cheung MC, Mai H, Letargo J, Chambers A, Sabharwal M, et
al. The impact of cancer drug wastage on economic evaluations: Economics
of Cancer Drug Wastage. Cancer. 2017 Sep 15;123(18):3583–90. DOI:
https://doi.org/10.1002/cncr.30807
8 Gilbar PJ, Chambers CR, Gilbar EC. Opportunities to significantly
reduce expenditure associated with cancer drugs. Future Oncology. 2017
Jun;13(15):1311–22. DOI: https://doi.org/10.2217/fon-2017-0033
9 Boby JM, Rajappa S, Mathew A. Financial toxicity in cancer care in
India: a systematic review. The Lancet Oncology. 2021 Dec
1;22(12):e541–9. DOI: .
https://doi.org/10.1016/S1470-2045(21)00468-X
10 Hess LM, Cui ZL, Li XI, Oton AB, Shortenhaus S, Watson IA. Drug
wastage and costs to the healthcare system in the care of patients with
non-small cell lung cancer in the United States. Journal of Medical
Economics. 2018 Aug 3;21(8):755–61. DOI:
https://doi.org/10.1080/13696998.2018.1467918
11 Bach PB, Conti RM, Muller RJ, Schnorr GC, Saltz LB. Overspending
driven by oversized single-dose vials of cancer drugs. BMJ. 2016 Feb
29;352:i788. DOI: https://doi.org/10.1136/bmj.i788
12 Liran O, Prus J, Gordon N, Almog V, Gruenewald T, Goldstein DA. A
real-world analysis of cancer drug wastage due to oversized vials.
Journal of the American Pharmacists Association. 2018 Nov;58(6):643–6.
DOI: https://doi.org/10.1016/j.japh.2018.06.004
13 Khandelwal N, Duncan I, Ahmed T, Rubinstein E, Pegus C. Impact of
Clinical Oral Chemotherapy Program on Wastage and Hospitalizations. JOP.
2011 May;7(3S):e25s–9s. DOI: DOI: 10.1200/JOP.2011.000301
15 Fasola G, Aprile G, Marini L, Follador A, Mansutti M, Miscoria M.
Drug waste minimization as an effective strategy of cost-containment in
Oncology. BMC Health Serv Res. 2014 Dec;14(1):57. DOI:
https://doi.org/10.1186/1472-6963-14-57
16 Nass SJ, Lustig TA, Amankwah FK, Shortliffe EH, National Academies of
Sciences, Engineering, and Medicine. Efforts to Reduce Discarded
Weight-Based Drugs. InMedications in Single-Dose Vials: Implications of
Discarded Drugs 2021 Feb 25. National Academies Press (US). DOI:
DOI: 10.17226/25911
17 Fahrenbruch R, Kintzel P, Bott AM, Gilmore S, Markham R. Dose
Rounding of Biologic and Cytotoxic Anticancer Agents: A Position
Statement of the Hematology/Oncology Pharmacy Association. JOP. 2018 Mar
1;14(3):e130–6. DOI: 10.1200/JOP.2017.025411